Filing Flows › Autolus Therapeutics (AUTL) › Q2 2026
Autolus Therapeutics (AUTL) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 11, 2026
Autolus Therapeutics (AUTL) reported revenue of $45.7M for the second quarter 2026 (Q2 2026), +118% from a year earlier and +74% from the quarter before. Operating margin was -95.9%, net loss $39.1M (85.6% of revenue).
Autolus Therapeutics, Q2 2026: revenue $45.7M (+118% year over year), operating margin -95.9%, net loss $39.1M, operating cash flow −$25.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $45.7M | +74% | +118% |
| Operating profit | −$43.8M | — | — |
| Net earnings | −$39.1M | — | — |
| Operating cash flow | −$25.1M | — | — |
What changed
Revenue was $45.7M in Q2 2026, up 118% year over year and up 74% from the previous quarter. Product revenue, net was the largest line at 100% of revenue. Product revenue, net added $24.7M year over year (up 118%), 100% of the total change.
Operating costs exceeded revenue by $43.8M, an operating margin of -95.9%. Total costs grew 9% against revenue growth of 118%. The fastest-growing cost line was SG&A (+36%). The quarter ended with a net loss of $39.1M, narrower than the previous quarter's $71.6M loss.
Operating cash flow was −$25.1M. Non-cash charges added back $2.2M of depreciation and amortization and $4.6M of share-based compensation. Working capital and other items added $7.3M. Capital expenditures of $913K exceeded it, leaving free cash flow of −$26.0M.
Questions
What was Autolus Therapeutics' revenue in the second quarter 2026?
Autolus Therapeutics (AUTL) reported revenue of $45.7M for the second quarter 2026 (Q2 2026), +118% from a year earlier and +74% from the quarter before.
Was Autolus Therapeutics profitable in the second quarter 2026?
Operating loss was $43.8M (-95.9% of revenue) and net loss $39.1M.